ALPCO Diagnostics recently launched an ELISA specific for measuring human sclerostin in serumplasma. Sclerostin inhibits osteoblast aivity via antagonism of the wnt signaling pathwayplays a key role in the regulation of bone formation. Reports show that sclerostin expression and/or circulating levels are elevated in osteoporosis, immobilization-induced bone loss, rheumatoid arthritis, multiple myelomabone metastases, making it a therapeutic target of great interest for the fields of bonecancer research. There are indications that sclerostin levels are also elevated with chronic kidney disease, suggesting relevance in the study of renal insufficiency as well.